Search

Memorial Sloan Kettering researchers have found a way to restore innate immune defense in the intestines and enhance resistance to a potentially harmful antibiotic-resistant bacterium.

… Monday, December 1, 2008 Summary Memorial Sloan Kettering researchers have found a way to restore innate immune defense in the intestines and enhance resistance to a potentially harmful antibiotic-resistant bacterium. Infection by antibiotic-resistant bacteria is a dangerous complication of broad-spectrum

Computational biologist Thomas Norman, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named one of 53 recipients of the prestigious 2020 National Institutes of Health (NIH) Director’s New Innovator Award. As part of the award, Dr. Norman will receive $1.5 million in direct costs upfront in the first year of a five-year award. 

… Tuesday, October 6, 2020 Computational biologist  Thomas Norman, PhD , of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) has been named one of 53 recipients of the prestigious 2020 National Institutes of Health (NIH) Director’s New Innovator Award. As part of the award, Dr. Norman will

Kravis WiSE promotes gender equity in science by providing stable funding and professional support for women in science at Memorial Sloan Kettering Cancer Center.

… Wednesday, March 6, 2024 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce four  Sloan Kettering Institute  (SKI) researchers have been named 2024  Marie-Josée Kravis WISE  fellowship grant recipients. Kravis WiSE was established in 2020, and is now in its fifth class. Kravis WISE remains

Recent findings by Memorial Sloan Kettering investigators suggest it might be possible to improve the effectiveness of chemotherapy for breast cancer by combining the treatment with a new type of drug called a cathepsin inhibitor.

… Friday, December 2, 2011 Summary Recent findings by Memorial Sloan Kettering investigators suggest it might be possible to improve the effectiveness of chemotherapy for breast cancer by combining the treatment with a new type of drug called a cathepsin inhibitor. Pictured: Genes & Development Journal

Deb Schrag, MD, MPH, FASCO, gastrointestinal medical oncologist and George J. Bosl Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK), has been elected 2027-28 President of the American Society of Clinical Oncology (ASCO), the world's leading professional organization for physicians and oncology professionals caring for people with cancer.

… Friday, December 19, 2025 Deb Schrag, MD, MPH, FASCO,   gastrointestinal medical oncologist and George J. Bosl Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK),   has been elected 2027-28 President of the  American Society of Clinical Oncology (ASCO ), the world’s leading

Researchers from MSK presented findings on graft-versus-host disease and other topics at the annual meeting of bone marrow transplant and cellular therapy experts.

… Monday, February 26, 2024 Doctors and scientists from Memorial Sloan Kettering Cancer Center (MSK) presented advances in transplantation and cellular therapies at a joint meeting hosted by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and

… Monday, September 16, 2024 Selwyn M. Vickers, MD, FACS , the President and CEO of Memorial Sloan Cancer Center, is a renowned pancreatic cancer surgeon, health equity researcher, and hospital leader. But the title he is proudest of is ‘Dad.’  Dr. Vickers and his wife, Janice, have raised four grown children

A recently approved treatment approach dramatically improves the outlook for people with an aggressive form of lymphoma.

… Friday, February 8, 2019 Summary People newly diagnosed with peripheral T cell lymphoma have traditionally been treated with chemotherapy. A recent study showed that adding a drug called brentuximab vedotin to chemotherapy could stop the disease from progressing and improve survival. Peripheral T cell

Three faculty members from Memorial Sloan Kettering Cancer Center (MSK) and Sloan Kettering Institute (SKI) have been elected to the 2021 class of American Association for the Advancement of Science (AAAS) Fellows.

… Thursday, January 27, 2022 Three faculty members from Memorial Sloan Kettering Cancer Center (MSK) and Sloan Kettering Institute (SKI) have been elected to the 2021 class of American Association for the Advancement of Science (AAAS) Fellows. The new class of AAAS Fellows includes 564 scientists, engineers

Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today, chimeric antigen receptor (CAR) T cells.

… Thursday, April 9, 2015 Researchers from Memorial Sloan Kettering Cancer Center (MSK) are pioneering a new groundbreaking clinical trial for children and young adults with relapsed or treatment-resistant acute lymphocytic leukemia (ALL) by using one of the most promising methods of cancer treatment today